Binding Beyond the Datasheet: A Selection Framework for UK Diagnostic Antibodies
Antibody datasheets often reduce performance to a single equilibrium dissociation constant. That number is not meaningless, but it is a poor substitute for a decision. In diagnostic development, the antibody is not binding a purified antigen in solution; it is part of a system. It may be coated onto a plastic surface, captured by a secondary reagent, exposed to serum or tissue, washed under stringency and detected through an enzyme or fluorophore. Each of those steps changes what binding actually means. UK diagnostic developers who choose on affinity alone risk selecting the reagent that looks best on paper and behaves least predictably in the assay.
What affinity does and does not tell you
Affinity describes the strength of a single binding interaction, usually expressed as a dissociation constant derived from association and dissociation rates. A lower dissociation constant indicates tighter binding under the conditions of the measurement. That is useful information. It is not a complete description of an antibody's behaviour in a diagnostic assay. Datasheet values may come from surface plasmon resonance, biolayer interferometry or another method, often using purified antigen in a defined buffer. The antigen in a clinical sample may be glycosylated differently, bound to a carrier protein, embedded in a membrane or partially degraded. The antibody in the assay may be immobilised in an orientation that obstructs its paratope. The buffer may contain blocking agents that alter kinetics.
Affinity also depends on valency. An immunoglobulin G molecule has two antigen-binding sites. When both sites engage epitopes on the same antigen or on adjacent antigens, the interaction can be much stronger than the sum of two independent monovalent interactions. This is avidity, sometimes called functional affinity. It is not a vague synonym for affinity; it is a property of the antibody–antigen system, including antigen density, spacing and mobility.
Avidity in ELISA and immunohistochemistry
In a sandwich ELISA, a bivalent detection antibody can bind two epitopes on a captured antigen, slowing dissociation and increasing signal. A capture antibody immobilised at high density can present antigen in a way that encourages bivalent engagement. Under one set of wash conditions, a moderate-affinity IgG may appear superior to a higher-affinity Fab fragment. Under another, the same IgG may produce higher background because avidity also amplifies weak, non-specific interactions. The lesson is not that avidity is good or bad; it is that avidity must be measured in the format that will be used.
Immunohistochemistry adds further variables. Fixation can modify epitopes, antigen retrieval can expose or destroy them, and tissue architecture can concentrate or mask targets. An antibody with strong apparent avidity may give intense staining that is not specific. A lower-affinity reagent may distribute more cleanly. Experienced histologists judge specificity alongside intensity, but the datasheet seldom provides the information needed for that judgement. UK diagnostic developers should treat published immunohistochemistry data as a starting point and confirm performance on the intended tissue types, with appropriate positive and negative controls.
Matrix interference is not a footnote
Diagnostic samples are not buffer. Serum and plasma contain heterophilic antibodies, rheumatoid factor and other binding proteins that can bridge capture and detection reagents. Urine varies in pH and salt concentration. Swab transport media can contain components that interfere with adsorption or enzyme activity. Tissue matrices contain endogenous biotin, peroxidase or pigments depending on the detection system. An antibody selected in phosphate-buffered saline may fail in the matrix that matters.
Matrix effects can also interact with avidity. A bivalent antibody may be more susceptible to bridging by endogenous immunoglobulins in a sandwich assay, producing false positives. Conversely, a high-avidity reagent may resist washing but also retain non-specifically on a plastic surface. These are empirical questions. They are answered by spike recovery, dilution linearity, precision studies and comparison with established methods in the intended sample type.
A practical decision framework
First, define the intended use and assay format before comparing candidates. A reagent for a manual ELISA used in a research setting has different requirements from one used in a high-throughput diagnostic workflow. Second, compare like with like. If one candidate is a monoclonal IgG and another is a Fab fragment, the comparison is not merely a comparison of affinity; it is a comparison of valency, size, clearance and detection options. Third, measure performance in the intended matrix across the clinically relevant range. A candidate that performs well at high antigen concentration may fail near the limit of detection.
Fourth, stress-test the conditions that avidity influences: wash stringency, incubation time, antigen density and blocking strategy. A short wash may flatter a high-avidity reagent; a stringent wash may reveal non-specific binding. Fifth, check lot-to-lot consistency and scale-up. A reagent that performs beautifully in a research lot may not be available in the quantity or consistency required for manufacturing. Sixth, document the decision and the residual risks. A design history file that records why a candidate was selected, and what was not tested, is more useful than a folder of datasheets.
The procurement conversation
UK diagnostic developers should ask suppliers for functional data in a comparable format, not just a headline affinity figure. Epitope information, clonality, purification method, formulation and lot-specific performance are all relevant. Suppliers cannot validate a customer's assay, but they can provide the information needed for a informed comparison. Buyers should be cautious about shorthand such as high affinity or diagnostic grade unless it is defined in relation to a stated application.
Regulatory expectations in the UK—whether under MHRA requirements, UKCA marking or a quality management system such as ISO 13485—place the burden of verification on the developer. That burden is easier to meet when selection is evidence-based from the outset. The question is not which antibody has the lowest dissociation constant. The question is which antibody, in this format, with this sample matrix and this detection chemistry, gives the most reliable result across the claimed measuring range.
Choose for the assay, not the abstract
Affinity is a starting point, not a verdict. Avidity, format and matrix interference are where diagnostic performance is decided. UK developers who build those variables into candidate selection will spend less time troubleshooting unexplained backgrounds and more time generating evidence that regulators, clinicians and laboratory users can trust. The datasheet is a summary; the assay is the argument.
